Professor Colin Baigent
Research groups
- Anaemic heart failure: factors associated with progression from severe morbidity to death among pregnant women in India
- Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU)
- Individual patient meta-analyses of randomized trials of aspirin for the primary prevention of cardiovascular disease (MRC PHRU)
- Medical Research Council Population Health Research Unit (MRC PHRU)
Websites
-
MRC Population Health Research Unit
Director
Colin Baigent
FMedSci
Professor of Epidemiology and Director, MRC PHRU
- Deputy Director, CTSU
Colin Baigent studied Medicine at Bristol and Oxford University (1983-89), having originally studied Mathematics at Oxford (1980-83).
He became an MRC career scientist in 2002, and in 2006 was appointed Professor of Epidemiology at Oxford. From July 2013, he became Deputy Director of CTSU.
His main interest is in cardiovascular epidemiology, and most particularly the design, conduct and application of large-scale randomised trials in cardiovascular disease. His research includes the coordination of meta-analyses of randomised trials, typically with individual participant data, resulting in landmark papers that have helped determine the effects of aspirin (and other antiplatelet drugs), non-steroidal anti-inflammatory drugs, fibrinolytic therapy, and statins in different types of patients. His group has also contributed to a better understanding of cardiovascular disease in patients with renal impairment through the Study of Heart and Renal Protection (SHARP), the largest ever in patients with moderate-to-severe chronic kidney disease (CKD), recruiting 9438 patients in nearly 400 hospitals in 18 countries.
Recent publications
-
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
Journal article
BAIGENT C. et al, (2022), The Lancet
-
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Journal article
Cholesterol Treatment Trialists’ Collaboration None., (2022), Clin Trials
-
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.
Journal article
Task Force for the management of COVID-19 of the European Society of Cardiology None. et al, (2022), Cardiovascular research, 118, 1385 - 1412
-
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2022), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
-
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.
Journal article
Task Force for the management of COVID-19 of the European Society of Cardiology None., (2022), European heart journal, 43, 1059 - 1103